Clinical Trial

Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study

Completed
View on ClinicalTrials.gov →
Summary
This study aims to provide an updated analysis of the resistance patterns of H. pylori in the Nanjing region, with a focus on characterizing the current status of phenotypic and genotypic resistance to these six antimicrobial agents. The findings are expected to offer a scientific basis for the rapid diagnosis and personalized treatment of H. pylori infection.
Protocol Amendment History 2 changes
critical Trial status changed: Not Yet Recruiting → Completed 2026-04-10
minor Completion moved earlier: 2026-05 -> 2026-03-25 2026-04-10
Trial Details
NCT Number NCT07455448
Lead Sponsor Nanjing First Hospital, Nanjing Medical University
Conditions HELICOBACTER PYLORI INFECTIONS
Enrollment 7,227 participants
Start Date 2026-03-01
Primary Completion 2026-03-25 (estimated)
Study Completion 2026-03-25 (estimated)
Updated on ClinicalTrials.gov 2026-04-09